부산대학교 도서관

To purchase or authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1742-1241.2007.01453.x Byline: M. Bianchi (1), M. Broggini (2), P. Balzarini (2), S. Franchi (1), P. Sacerdote (1) Abstract: Summary Objective: This study was designed to investigate the analgesic effects of nimesulide and celecoxib in patients with knee osteoarthritis (OA). In patients with joint effusion, the effects of these non-steroidal anti-inflammatory drugs (NSAIDs) on synovial fluid concentrations of substance P (SP), interleukin (IL)-6 and IL-8 also were evaluated. Methods: Patients were randomly assigned either nimesulide (100 mg twice a day) or celecoxib (200 mg once a day) for 2 weeks. The intensity of joint pain was assessed with a 100-mm visual analogue scale (VAS). Furthermore, patients completed questions about analgesic efficacy and overall tolerability of the treatments on a five-point categorial scale. Synovial fluid samples were drawn at baseline, 30 min after the first drug intake (day 1), and 30 min after the last drug intake (day 14). Results: We enrolled 44 patients, 20 of whom had a joint effusion. In this group, the effects of nimesulide were more marked than for celecoxib, with evidence of a faster onset of the analgesic action. Both after a single or repeated administration, nimesulide significantly reduced the synovial fluid concentrations of SP and IL-6. Celecoxib, on the other hand, did not change the concentrations of SP and significantly reduced the levels of IL-6 only on day 14. None of the drugs affected IL-8. Both drugs were generally well tolerated. Conclusions: These results provide evidence that nimesulide is an effective agent for the symptomatic treatment of OA. The effect on inflammatory pain mediators is consistent with the fast analgesic action of this NSAID. Author Affiliation: (1)Department of Pharmacology, University of Milan, Milan, Italy (2)Unit of Rheumatology, A.O. Ospedale di Circolo e Fondazione Macchi, Varese, Italy Article History: Paper received December 2006, accepted April 2007 Article note: Mauro Bianchi, MD, Department of Pharmacology, Via Vanvitelli, 32, 20129 Milan, Italy, Tel.: + 39 02 50316930, Fax: + 39 02 50316949, Email: mauro.bianchi@unimi.it